Patent Trial and Appeal Board invalidates Zytiga's 2027 patent and opens the way for generic competition.- Johnson & Johnson.
. Johnson & Johnson's prostate cancer therapy Zytiga (abiraterone acetate) faces the prospect of generics this year- 2018-, as a patent-office ruling has invalidated its last remaining patent. The U.S. Patent Trial and Appeal Board invalidated Zytiga's 2027 patent after an inter partes review challenge by generics maker Argentum Pharmaceuticals. Zytiga generics could come to the market as soon as October 2018.
Johnson & Johnson stated that they believed the '438 patent is valid and will continue to vigorously defend it.
Comment: More than 50% of Zytiga's sales come from outside of the U.S., where the drug has protection until 2022.
Learning Zones
The Learning Zones are an educational resource for healthcare professionals that provide medical information on the epidemiology, pathophysiology and burden of disease, as well as diagnostic techniques and treatment regimens.